The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry

Autoři	STEFANIKOVA Marianna DOUBKOVÁ Martina OVESNÁ Petra STERCLOVA Martina LACINA Ladislav ZURKOVA Monika PLACKOVA Martina BARTOS Vladimir JANICKOVA Ivana BITTENGLOVA Radka ANTON Jan SÝKOROVÁ Lubica LOSTAKOVA Vladimira MUSILOVA Pavlina SULDOVA Hana MOKOSOVA Radka DIDYK Jurij SISAKOVA Lenka LISA Pavlina LNENICKA Jaroslav DARICKOVA Hana DOLEZEL Daniel PSIKALOVA Jana TYL Richard KRALOVA Renata KOZIAR VASAKOVA Martina
Rok publikování	2023
Druh	Článek v odborném periodiku
Časopis / Zdroj	BMC Pulmonary Medicine
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-023-02450-3
Doi	http://dx.doi.org/10.1186/s12890-023-02450-3
Klíčová slova	Idiopathic pulmonary fibrosis; Nintedanib; Lung function decline; Overall survival
Popis	IntroductionThe antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic treatment outcome in real-world cohorts of Czech EMPIRE registry.Patients/methodsData of 611 Czech IPF subjects, 430 (70%) treated with nintedanib (NIN group), 181 (30%) with no-antifibrotic treatment (NAF group) were analysed. The influence of nintedanib on overall survival (OS), pulmonary function parameters as forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO), as well as GAP score (gender, age, physiology) and and CPI (composite physiological index) were investigated.ResultsDuring 2 year follow-up we observed that nintedanib treated patients had longer OS, compared to those treated with no-antifibrotic drugs (p < 0.00001). Nintedanib reduces risk of mortality over no-antifibrotic treatment by 55% (p < 0.001). We have observed no significant difference in the rate of FVC and DLCO decline between the NIN and NAF group. Changes within 24 months from baseline in CPI were not significant between the groups (NAF and NIN).ConclusionOur real-practice study showed the benefit of nintedanib treatment on survival. There were no significant differences between NIN and NAF groups in changes from baseline in FVC %, DLCO % predicted and CPI.